Overview

Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD

Status:
NOT_YET_RECRUITING

Trial end date:
2027-04-01

Target enrollment:

Participant gender:

Summary

To evaluate the safety and efficacy of ripertamab and its combination with tacrolimus in the initial treatment of MCD to provide a treatment regimen with higher remission rates, lower recurrence rates, and fewer side effects in patients with MCD.

Phase:

PHASE3

Details

Lead Sponsor:

Air Force Military Medical University, China

Collaborators:

First Affiliated Hospital Xi'an Jiaotong University
Second Affiliated Hospital of Xi'an Jiaotong University
Shaanxi Provincial Hospital of Chinese Medicine
Shaanxi Provincial People's Hospital
The Second Affiliated Hospital of Air Force Military Medical University

Treatments:

Control Groups